R&D

Drug Development Portfolio

Drug License Feasibility Preclinical Clinical trials Regulatory
Submissions
Approved Sales
(royalties)

iNKT cell platform (oncology)

CAR19-iNKT
Second CAR-iNKT target
New CAR-iNKT
Additional Indications

Anagrelide (solid tumors)

ZolpiMist (insomnia)*

Sumatriptan (migraine)

Medical Grade Cannabis

Undisclosed

*ZolpiMist has been approved by the TGA and the FDA. SUDA holds the licence to ZolpiMist outside of North America